Orchestra BioMed Holdings, Inc. - Ordinary Shares (OBIO) earnings
OBIO earnings moved a median of +1.34% by the close. Quarterly and annual OBIO reports and results, each read against the price at its own news timestamp. Back to the OBIO overview →
16 measured OBIO earnings events.
Where these OBIO earnings landedvs 14 measured OBIO earnings reactions
| Middle 50% of OBIO earnings reactions | -3.54% to +9.02% |
|---|---|
| Median reaction (to close) | +1.34% |
| Measured reactions | 14 |
Point-in-time · zero look-ahead
Half of the 14 OBIO earnings events with a measured close landed between -3.54% and +9.02%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Orchestra BioMed Holding For: Mar 31 | SEC filing · Form 10-Q | -0.74% | -0.25% | |
| Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | Press release | -0.74% | -0.25% | |
| Form 10-K Orchestra BioMed Holding For: Dec 31 | SEC filing · Form 10-K | -0.11% | -4.99% | |
| Form 10-Q Orchestra BioMed Holding For: Sep 30 | SEC filing · Form 10-Q | +0.67% | +9.33% | |
| Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | Press release | +0.67% | +9.33% | |
| Form 10-Q Orchestra BioMed Holding For: Jun 30 | SEC filing · Form 10-Q | +1.23% | — | |
| Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates | Press release | +1.23% | — | |
| Form 10-Q Orchestra BioMed Holding For: Mar 31 | SEC filing · Form 10-Q | -1.84% | +8.09% | |
| Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones | Press release | -1.84% | +8.09% | |
| Form 10-K Orchestra BioMed Holding For: Dec 31 | SEC filing · Form 10-K | +3.63% | -16.06% | |
| Form 10-Q Orchestra BioMed Holding For: Sep 30 | SEC filing · Form 10-Q | -1.50% | +1.34% | |
| Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update | Press release | -1.50% | +1.34% | |
| Form 10-Q Orchestra BioMed Holding For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -4.64% | |
| Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update | Press release | +0.00% | -4.64% | |
| Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update | Press release | +0.00% | +13.04% | |
| Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.43% | +17.76% |
Keep exploring
More OBIO: analyst actions → · SEC filings → · OBIO overview →